Funders › NY › Emerald Foundation Inc Co Solomon Blum Heymann › 2020
Grants paid by Emerald Foundation Inc Co Solomon Blum Heymann, tax year 2020
EIN 13-3912580 · New York, NY · Form 990-PF, Part XV · NTEE T20J
In tax year 2020, Emerald Foundation Inc Co Solomon Blum Heymann (EIN 13-3912580) reported 10 grants paid totaling $1,125,000. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2020
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2020 | Regents of the University of California La Jolla, CA | U | $150,000 | paid | To (1) define a microbiome growth curce in healthy children, (2) determine when and why deviation from this curve occurs, and (3) investigate known, as well as discover new, microbiome-linked disorders and relationships among them, and analyze microbiome associations with clinical presentations of COVID-19. | 202112879349101111 |
| 2020 | Rockefeller University New York, NY | B | $150,000 | paid | To investigate the role of tRNA-derived fragments and the genes they regulate in breast cancer progression and metastasis. | 202112879349101111 |
| 2020 | Brigham and Women's Hospital Inc Boston, MA | C | $150,000 | paid | To uncover and validate druggable targets that can be combined with MEK/ERK inhibitors to treat RAS pathway-driven malignancies, especially melanoma. | 202112879349101111 |
| 2020 | Massachusetts Institute of Technology Cambridge, MA | B | $150,000 | paid | To investigate the role of diet and nutrient availability in tumor growth, progression, and response to treatment. | 202112879349101111 |
| 2020 | University of California San Francisco San Francisco, CA | C | $150,000 | paid | To develop a small molecule that stabilizes mutant P53 in cancer and further elaborate this compound with the ability to increase DNA binding of bound P53. | 202112879349101111 |
| 2020 | Memorial Sloan-Kettering Cancer Center New York, NY | U | $75,000 | paid | To investigate the molecular mechanisms underlying how endgogenous DNA-modifying enzymes lead to cancer genome evolution. | 202112879349101111 |
| 2020 | Nyu School of Medicine New York, NY | U | $75,000 | paid | To investigate how metabolic rewiring in distinct genetic subtypes of lung cancer impacts immune cell infiltration and leads to immune evasion. | 202112879349101111 |
| 2020 | Salk Institute for Biological Studies La Jolla, CA | B | $75,000 | paid | To investigate the potential of CA19-9 as a therapeutic target for pancreatic cancer treatment and to discover pharmacological approaches to blocking CA19-9 production in malignant cells. | 202112879349101111 |
| 2020 | University of Chicago Chicago, IL | U | $75,000 | paid | To identify combinations of commensal bacterial isolates that suppress Klebsiella pneumoniae in the colon and the underlying cooperative mechanisms of this activity. | 202112879349101111 |
| 2020 | Dana-Farber Cancer Institute Boston, MA | B | $75,000 | paid | To optimize USP8 inhibitors and test their activity in models of neurodegenerative disease, non-small cell lung cancer, and other applicable systems. | 202112879349101111 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.